Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

doi:10.1016/S0140-6736(17)31585-4

The Lancet

Volume 390, Issue 10103, 7–13 October 2017, Pages 1664-1675

https://doi.org/10.1016/S0140-6736(17)31585-4 Get rights and content

Summary

Background

Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has neuroprotective effects in preclinical models of Parkinson's disease. We investigated whether these effects would be apparent in a clinical trial.

Methods

In this single-centre, randomised, double-blind, placebo-controlled trial, patients with moderate Parkinson's disease were randomly assigned (1:1) to receive subcutaneous injections of exenatide 2 mg or placebo once weekly for 48 weeks in addition to their regular medication, followed by a 12-week washout period. Eligible patients were aged 25–75 years, had idiopathic Parkinson's disease as measured by Queen Square Brain Bank criteria, were on dopaminergic treatment with wearing-off effects, and were at Hoehn and Yahr stage 2·5 or less when on treatment. Randomisation was by web-based randomisation with a two strata block design according to disease severity. Patients and investigators were masked to treatment allocation. The primary outcome was the adjusted difference in the Movement Disorders Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor subscale (part 3) in the practically defined off-medication state at 60 weeks. All efficacy analyses were based on a modified intention-to-treat principle, which included all patients who completed any post-randomisation follow-up assessments. The study is registered at ClinicalTrials.gov (NCT01971242) and is completed.

Findings

Between June 18, 2014, and March 13, 2015, 62 patients were enrolled and randomly assigned, 32 to exenatide and 30 to placebo. Our primary analysis included 31 patients in the exenatide group and 29 patients in the placebo group. At 60 weeks, off-medication scores on part 3 of the MDS-UPDRS had improved by 1·0 points (95% CI −2·6 to 0·7) in the exenatide group and worsened by 2·1 points (−0·6 to 4·8) in the placebo group, an adjusted mean difference of −3·5 points (−6·7 to −0·3; p=0·0318). Injection site reactions and gastrointestinal symptoms were common adverse events in both groups. Six serious adverse events occurred in the exenatide group and two in the placebo group, although none in either group were judged to be related to the study interventions.

Interpretation

Exenatide had positive effects on practically defined off-medication motor scores in Parkinson's disease, which were sustained beyond the period of exposure. Whether exenatide affects the underlying disease pathophysiology or simply induces long-lasting symptomatic effects is uncertain. Exenatide represents a major new avenue for investigation in Parkinson's disease, and effects on everyday symptoms should be examined in longer-term trials.

Funding

Michael J Fox Foundation for Parkinson's Research.

Introduction

Perhaps the most important unmet need in Parkinson's disease is the development of a neuroprotective or disease-modifying therapy that can slow or halt disease progression. None of the compounds that had potential neuroprotective properties in in-vitro or animal models have shown any effects on disease progression in clinical trials.¹

Glucagon-like peptide-1 (GLP-1) agonists are licensed for the treatment of type 2 diabetes. These drugs activate GLP-1 receptors to promote glucose-level-dependent insulin secretion, inhibit glucagon secretion, and slow gastric emptying.² Exenatide is a synthetic version of exendin-4, a naturally occurring analogue of human GLP-1 that was originally discovered in the saliva of the Gila monster (Heloderma suspectum) and is resistant to the normal metabolic processes that degrade endogenous human GLP-1.³ In addition to effects on glucose homoeostasis, evidence from studies in toxin-based rodent models of Parkinson's disease show that exenatide crosses the blood–brain barrier and exerts neuroprotective and neurorestorative effects via GLP-1 receptors at doses similar to those used in type 2 diabetes, resulting in improvements in motor performance, behaviour, learning, and memory.4, 5, 6, 7, 8

We previously did a small, proof-of-concept, open-label trial⁹ of exenatide in patients with Parkinson's disease of moderate severity. 12 months' exposure to exenatide led to improvements in motor and cognitive assessments in the intervention group compared with the control group, which persisted 12 months after drug withdrawal.¹⁰ On the basis of these encouraging findings, we aimed to do a randomised, placebo-controlled trial (NCT01971242) to assess further the potential disease-modifying effects of 48 weeks' exposure to exenatide, followed by a 12-week washout, on the motor severity of Parkinson's disease.

Research in context

Evidence before this study

We searched PubMed with the terms “Parkinson's disease”, “glucagon-like peptide-1”, “exenatide”, “trial”, “neuroprotection”, and “disease modification” for articles published in English on or before Dec 4, 2016 (the date of our final search), in any field. We identified several preclinical studies of exenatide, a glucagon-like peptide-1 agonist, which showed neuroprotective and neurorestorative effects in experimental animal-toxin models of Parkinson's disease. We also identified a proof-of-concept study of exenatide as a possible disease-modifying treatment in patients with Parkinson's disease. In this open-label trial, 21 patients who received 12 months of exenatide injections in addition to their regular drugs had a mean improvement of 2·7 points on the Movement Disorders Society Unified Parkinson's Disease Rating Scale part 3, compared with a deterioration of 2·2 points in 24 patients in the control group who received their regular drugs only (mean difference 4·9, 95% CI 0·3–9·4; p=0·037). Furthermore, patients treated with exenatide had a significant improvement on a cognitive assessment scale compared with those in the control group (mean difference 5·0, 95% CI 9·2–0·8; p=0·006). Persistent significant benefits were noted in the exenatide group compared with the control group in motor disability and cognitive function 12 months after the withdrawal of exenatide. However, because a placebo control was not used, these data could not be interpreted as proof of efficacy.

Added value of this study

To our knowledge, ours is the first randomised, placebo-controlled trial of exenatide as a potential disease-modifying drug in Parkinson's disease. After 48 weeks, patients given 2 mg exenatide weekly had a significant advantage in terms of the primary outcome, the Movement Disorders Society Unified Parkinson's Disease Rating Scale part 3, compared with those given placebo. This difference between groups was still significant after a 12-week drug washout period. Our study is also the first to show that exenatide, when given at licensed diabetes doses, crosses the blood–brain barrier and is detectable in cerebrospinal fluid in concentrations similar to those in preclinical models of Parkinson's disease, which are associated with advantageous outcomes. Exenatide was well tolerated, although injection site reactions and gastrointestinal symptoms were noted.

Implications of all the available evidence

We have replicated the results of our previous clinical study and shown that patients with Parkinson's disease who were given exenatide had improvements in the practically defined off-medication motor scores of Parkinson's disease compared with those given placebo. Whether exenatide affects the underlying pathophysiology of Parkinson's disease or simply induces long-lasting symptomatic effects remains uncertain. However, these results represent a major new avenue for investigation in the treatment of Parkinson's disease.

Section snippets

Study design and participants

We did a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial of exenatide once weekly in Parkinson's disease of moderate severity. The trial was done at the Leonard Wolfson Experimental Neuroscience Centre (London, UK), a dedicated clinical trial research facility and part of the University College London (UCL) Institute of Neurology and the National Hospital for Neurology & Neurosurgery. The study was coordinated by the UCL Comprehensive Clinical Trials Unit

Results

Between June 18, 2014, and March 13, 2015, 68 patients were screened for eligibility, 62 of whom were randomly assigned to either exenatide or placebo (figure 1). Patients randomly allocated to exenatide were slightly older, had higher baseline MDS-UPDRS part 3 scores, and had lower LED than did those assigned to placebo (table 1). Questionnaire responses and collection of empty drug vials at each visit suggested that compliance with study drugs was very high: 58 patients reported not missing a

Discussion

In this randomised, double-blind, placebo-controlled, parallel-group, single-centre trial, patients with Parkinson's disease of moderate severity given exenatide for 48 weeks had a significant advantage of 3·5 points on part 3 of the MDS-UPDRS in an off-medication state compared with those given placebo 12 weeks after stopping exenatide. However, no significant differences were noted between the exenatide and placebo groups in scores on parts 1–4 of the MDS-UPDRS (in the on-medication state),

References (36)

J Eng et al.
Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas
J Biol Chem
(1992)
N Rampersaud et al.
Exendin-4 reverses biochemical and behavioral deficits in a pre-motor rodent model of Parkinson's disease with combined noradrenergic and serotonergic lesions
Neuropeptides
(2012)
S Kim et al.
Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease
J Endocrinol
(2009)
M Elashoff et al.
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Gastroenterology
(2011)
D Athauda et al.
Challenges in detecting disease modification in Parkinson's disease clinical trials
Parkinsonism Relat Disord
(2016)
D Athauda et al.
The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action
Drug Discov Today
(2016)
Y Chen et al.
Neuroprotective effects of geniposide in the MPTP mouse model of Parkinson's disease
Eur J Pharmacol
(2015)
D Athauda et al.
Insulin resistance and Parkinson's disease: a new target for disease modification?
Prog Neurobiol
(2016)
JB Buse et al.
Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
Lancet
(2013)
JB Buse et al.
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
Lancet
(2009)

W Liu et al.

Neuroprotective effects of lixisenatide and liraglutide in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

Neuroscience

(2015)

D Athauda et al.

The ongoing pursuit of neuroprotective therapies in Parkinson disease

Nat Rev Neurol

(2014)

JA Lovshin et al.

Incretin-based therapies for type 2 diabetes mellitus

Nat Rev Endocrinol

(2009)

A Harkavyi et al.

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

J Neuroinflammation

(2008)

Y Li et al.

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

PNAS

(2009)

G Bertilsson et al.

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease

J Neurosci Res

(2008)

I Aviles-Olmos et al.

Exenatide and the treatment of patients with Parkinson's disease

J Clin Invest

(2013)

I Aviles-Olmos et al.

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease

J Parkinsons Dis

(2014)

Cited by (509)

GLP-1 modulated the firing activity of nigral dopaminergic neurons in both normal and parkinsonian mice
2024, Neuropharmacology
The spontaneous firing activity of nigral dopaminergic neurons is associated with some important roles including modulation of dopamine release, expression of tyrosine hydroxylase (TH), as well as neuronal survival. The decreased neuroactivity of nigral dopaminergic neurons has been revealed in Parkinson's disease. Central glucagon-like peptide-1 (GLP-1) functions as a neurotransmitter or neuromodulator to exert multiple brain functions. Although morphological studies revealed the expression of GLP-1 receptors (GLP-1Rs) in the substantia nigra pars compacta, the possible modulation of GLP-1 on spontaneous firing activity of nigral dopaminergic neurons is unknown. The present extracellular in vivo single unit recordings revealed that GLP-1R agonist exendin-4 significantly increased the spontaneous firing rate and decreased the firing regularity of partial nigral dopaminergic neurons of adult male C57BL/6 mice. Blockade of GLP-1Rs by exendin (9–39) decreased the firing rate of nigral dopaminergic neurons suggesting the involvement of endogenous GLP-1 in the modulation of firing activity. Furthermore, the PKA and the transient receptor potential canonical (TRPC) 4/5 channels are involved in activation of GLP-1Rs-induced excitatory effects of nigral dopaminergic neurons. Under parkinsonian state, both the exogenous and endogenous GLP-1 could still induce excitatory effects on the surviving nigral dopaminergic neurons. As the mild excitatory stimuli exert neuroprotective effects on nigral dopaminergic neurons, the present GLP-1-induced excitatory effects may partially contribute to its antiparkinsonian effects.
Immunomodulation and inflammation: Role of GLP-1R and GIPR expressing cells within the gut
2024, Peptides
Glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are peptide hormones produced by enteroendocrine cells in the small intestine. Despite being produced in the gut, the leveraging of their role in potentiating glucose-stimulated insulin secretion, also known as the incretin effect, has distracted from discernment of direct intestinal signaling circuits. Both preclinical and clinical evidence have highlighted a role for the incretins in inflammation. In this review, we highlight the discoveries of GLP-1 receptor (GLP-1R)+ natural (TCRαβ and TCRγδ) and induced (TCRαβ+CD4+ cells and TCRαβ+CD8αβ+) intraepithelial lymphocytes. Both endogenous signaling and pharmacological activation of GLP-1R impact local and systemic inflammation, the gut microbiota, whole-body metabolism, as well as the control of GLP-1 bioavailability. While GIPR signaling has been documented to impact hematopoiesis, the impact of these bone marrow-derived cells in gut immunology is not well understood. We uncover gaps in the literature of the evaluation of the impact of sex in these GLP-1R and GIP receptor (GIPR) signaling circuits and provide speculations of the maintenance roles these hormones play within the gut in the fasting-refeeding cycles. GLP-1R agonists and GLP-1R/GIPR agonists are widely used as treatments for diabetes and weight loss, respectively; however, their impact on gut homeostasis has not been fully explored. Advancing our understanding of the roles of GLP-1R and GIPR signaling within the gut at homeostasis as well as metabolic and inflammatory diseases may provide targets to improve disease management.
Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis
2024, European Neuropsychopharmacology
The study addresses concerns about potential psychiatric side effects of Glucagon-like peptide-1 receptor agonists (GLP-1 RA).
The aim of this work was to analyse adverse drug reports (ADRs) from the Food and Drug Administration Adverse Events Reporting System (FAERS) using metformin and orlistat as comparators.
Descriptive and pharmacovigilance disproportionality analyses was performed.
A total of 209,354 ADRs were reported, including 59,300 serious cases. Of those, a total of 5378 psychiatric disorder cases, including 383 ‘serious’ cases related to selected ADRs were registered during 2005–2023. After unmasking, 271 cases where individual GLP-1 RA were implicated showing liraglutide (n = 90; Reported Odds Ratio (ROR) = 1.64), exenatide (n = 67; ROR = 0.80), semaglutide (n = 61; ROR = 2.03), dulaglutide (n = 45; ROR = 0.84), tirzepatide (n = 5; ROR = 1.76) and albiglutide (n = 2; ROR = 0.04). A greater association between these ADRs with metformin was observed, but not orlistat. With regards to selected preferred terms (PTs), 42 deaths including 13 completed suicides were recorded. Suicidal ideation was recorded in n = 236 cases for 6/7 GLP-1 RA (excluding lixisenatide).
Suicide/self-injury reports pertaining to semaglutide; tirzepatide; and liraglutide were characterised, although lower than metformin. It is postulated that rapid weight loss achieved with GLP-1 RA can trigger significant emotional, biological, and psychological responses, hence possibly impacting on suicidal and self-injurious ideations.
With the current pharmacovigilance approach, no causality link between suicidal ideation and use of any GLP-1 RA can be inferred. There is a need for further research and vigilance in GLP-1 RA prescribing, particularly in patients with co-existing psychiatric disorders.
Metformin use is associated with reduced mortality risk in diabetic patients with Parkinson's disease
2024, Clinical Nutrition ESPEN
Parkinson's disease (PD) and type-2 diabetes (T2D) arguably share pathophysiologic mechanisms, resulting in a more severe phenotype and progression and diabetes is currently considered a risk factor of PD. Besides, research suggests antidiabetic therapies as potential disease-modifying strategies. The main aim was to assess the impact of a metformin-inclusive antidiabetic treatment on patient all-cause mortality.
A nested case–control prospective study including newly diagnosed PD patients reporting the onset of T2D within ±2 years from the onset of PD (n = 159) and matched (1:5; gender, year of PD onset and age at PD onset) non-diabetic cases (n = 795) followed until death or censoring. Patients on a metformin-inclusive treatment regimen were compared to those receiving other oral anti-diabetics (OADs).
Among patients with T2D, 123 were treated with a drug regimen containing metformin (alone [65.0%] or in combination with other drugs [35.0%]) and 36 were prescribed other OADs. During a median PD duration of 96 months [IQR, 60–144], 171 patients died. Diabetes was not associated with reduced survival: fully-adjusted HR = 1.19 [95%CI, 0.81–1.76] (P = 0.37). After stratifying for T2D treatment, a metformin-inclusive regimen was not associated with increased risk of death (HR = 1.06 [95%CI, 0.61–1.84]; P = 0.83), while patients receiving other OADs had reduced survival (HR = 1.83 [95%CI, 1.01–3.32]; P = 0.034).
Metformin use was not associated with increased risk of death in diabetic patients with PD reporting concomitant onset of the two diseases. Metformin appears to be a promising disease-modifying therapy given also the preclinical background, low cost and satisfactory safety and tolerability. Further studies are warranted to investigate its impact on disease progression.
Nanocarriers to mediate the pathways from diabetes toward Parkinson's disease
2024, Journal of the Taiwan Institute of Chemical Engineers
The connection between type 2 diabetes mellitus (T2DM) and Parkinson's disease (PD) was first pointed out in the early 1960s. This probable link is still under serious consideration nowadays.
Neurological changes caused by T2DM could be relevant to PD that included neuroinflammation, dopaminergic deregulation, reduction in the expression of peroxisome proliferator-activated receptor-gamma coactivator 1-alpha, increment in the expression of phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes 15 and acceleration of alpha-synuclein (α-Syn) amyloid fibril formation. Furthermore, medical evidence disclosed that significantly exacerbated PD symptoms were associated with the initiation of T2DM, and common genes were concurrently found in DNA of T2DM and PD patients. Insulin resistance and microbiota dysbiosis of the gut-brain axis also connected DM to PD, explaining DM could be a risk factor for PD. In terms of treatment, antidiabetic drugs appeared to engender a certain degree of neuroprotective activity against PD. During drug delivery to the central nervous system, biomaterials could play a crucial role in permeating the blood-brain barrier (BBB) and recognizing exact cerebral tissue to rescue neurons from degeneration. Exosomes, liposomes, micelles, solid lipid nanoparticles, dendrimers, niosomes and nano-sized polymers have been developed to enhance drug and gene efficacy in brain targeting for PD management. In order to boost BBB permeability and α-Syn conjugation, the surface of these nanocarriers (NCs) were modified with active biomolecules, for instance, lactoferrin, angiopep and OX26. Natural exosomes were exposed to a limited number, and can be an efficient vector in analyzing the pathways from DM toward PD for clinical trials.
This review focuses on understanding the pathophysiological relation between T2DM and PD, and the treatment for the two diseases with NCs. We also highlight the problems that have been solved and the challenges that continue.
Pharmacological interventions in human aging
2024, Ageing Research Reviews
Pharmacological interventions are emerging as potential avenues of alleviating age-related disease. However, the knowledge of ongoing clinical trials as they relate to aging and pharmacological interventions is dispersed across a variety of mediums. In this review we summarize 136 age-related clinical trials that have been completed or are ongoing. Furthermore, we establish a database that describe the trials (AgingDB, www.agingdb.com) keeping track of the previous and ongoing clinical trials, alongside their outcomes. The aim of this review and database is to give people the ability to easily query for their trial of interest and stay up to date on the latest results. In sum, herein we give an overview of the current pharmacological strategies that have been applied to target human aging.

View all citing articles on Scopus

View full text

ArticlesExenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial